Medications That Interact with St. John's Wort

Introduction to St. John's Wort Interactions

St. John's wort is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), which can significantly decrease the plasma concentrations and effectiveness of many medications, potentially leading to treatment failure and adverse clinical outcomes, as noted by the American Heart Association and the American College of Physicians 1, 2

Major Drug Interactions with St. John's Wort

Patients taking warfarin should avoid St. John's wort due to the risk of reduced anticoagulant effect, as recommended by the American College of Cardiology 1
The American College of Obstetricians and Gynecologists notes that St. John's wort can reduce the effectiveness of oral contraceptives, potentially leading to unintended pregnancy 2, 3
Concomitant use of St. John's wort with selective serotonin reuptake inhibitors (SSRIs) or monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of serotonin syndrome, according to the American Psychiatric Association 2, 4
The American College of Cardiology recommends that ivabradine is specifically contraindicated with St. John's wort due to reduced effectiveness 5

Interactions with Other Medications

St. John's wort can significantly decrease the plasma concentration of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors, as reported by the Infectious Diseases Society of America 6
The National Comprehensive Cancer Network warns that imatinib plasma concentrations may be decreased when taken with St. John's wort, potentially requiring dose adjustments 7
The American Academy of Neurology notes that St. John's wort may decrease levels of anticonvulsants like carbamazepine, phenytoin, and phenobarbital 2

Clinical Implications and Management

The American Society of Anesthesiologists recommends that St. John's wort should be discontinued at least 2 weeks before surgery due to multiple potential drug interactions and effects on serotonin levels 8
If a patient is taking St. John's wort with medications known to interact, more frequent monitoring of drug levels or therapeutic effects is recommended, as advised by the American College of Clinical Pharmacy 1

Important Considerations

The American Medical Association notes that St. John's wort is not regulated by the FDA, and there is no standardization of content or potency 2
Patients should always disclose use of St. John's wort to healthcare providers, particularly before starting new medications or undergoing surgical procedures, as recommended by the Mayo Clinic 8

Cytochrome P450 Enzyme Modification by St. John's Wort

Mechanism of Action

St. John's wort induces CYP3A4 and P-gp, accelerating the metabolism and elimination of substrate drugs, thereby reducing their therapeutic effectiveness, as noted by the American Heart Association 9
This contrasts with other herbs like ginkgo, ginger, ginseng, and garlic, which primarily inhibit the cytochrome P450 system, resulting in prolonged drug effects and increased blood concentrations, according to the American Academy of Pediatrics 10, 11

Critical Drug Interactions

Cardiovascular Medications

Statins, such as atorvastatin, lovastatin, and simvastatin, may have their levels significantly reduced due to CYP3A4 induction by St. John's wort, as reported in Circulation 9

Other High-Risk Interactions

Immunosuppressants, including midazolam, cyclosporine, and tacrolimus, may have their concentrations affected by St. John's wort, as noted by the American Academy of Pediatrics 10, 11

Clinical Management

Monitoring Requirements

Patients taking St. John's wort with interacting medications should be monitored more frequently for drug levels or therapeutic effects, and a complete herbal supplement history should be obtained, as recommended by the American Academy of Pediatrics 10, 11

Important Considerations

Grapefruit juice inhibits intestinal CYP3A4, increasing drug bioavailability, which is distinct from St. John's wort's inducing effect, as reported in Pediatrics and Circulation 9, 12, 13

St. John's Wort and Escitalopram Interaction Guidelines

Clinical Considerations

The American College of Physicians notes insufficient evidence about the applicability, purity, and potency of St. John's Wort preparations available in the United States, highlighting the need for caution when considering concomitant use with escitalopram 14, 15
Monitoring for at least 24-48 hours after discontinuing St. John's Wort is recommended, as symptoms of serotonin syndrome can emerge during this period 16
The interaction between St. John's Wort and escitalopram can lead to reduced efficacy of oral contraceptives, anticoagulants, immunosuppressants, and cardiovascular medications, including warfarin, cyclosporine, tacrolimus, digoxin, and statins 17, 18
Photosensitivity is increased when combining escitalopram and St. John's Wort, as both can cause photosensitive reactions 19

St. John's Wort Drug Interactions

Mechanism and Clinical Implications

St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein, significantly reducing plasma concentrations of numerous medications, potentially causing treatment failure, organ rejection, unintended pregnancy, and life-threatening complications 20
The interaction between St. John's wort and other medications persists for several months after discontinuation due to the herb's long-lasting enzymatic effects 20

Critical Drug Interactions

St. John's wort reduces the effectiveness of combined oral contraceptives, leading to unintended pregnancies, as reported by the American Academy of Pediatrics 21
The use of St. John's wort with amiodarone and sofosbuvir-based regimens can lead to life-threatening arrhythmias, according to the European Association for the Study of the Liver 20
St. John's wort is contraindicated with sofosbuvir and sofosbuvir/velpatasvir due to reduced drug exposure and potential treatment failure, as recommended by the European Association for the Study of the Liver 20

Interaction Between St. John’s Wort and Alprazolam

Guideline Recommendations

The U.S. Public Health Service guidelines list alprazolam (as well as midazolam and triazolam) as contraindicated when co‑administered with St. John’s wort because of the risk of serious adverse events such as unpredictable sedation or respiratory depression. 22
The same Public Health Service guideline emphasizes that the interaction is mediated by CYP3A4 induction, leading to markedly reduced alprazolam plasma concentrations and loss of therapeutic effect. 23

Alternative Management Strategies

For patients who need treatment for both anxiety and depression, cognitive‑behavioral therapy or second‑generation antidepressants (SSRIs) are recommended as first‑line options instead of St. John’s wort. 24
When depression is treated with St. John’s wort, clinicians should avoid benzodiazepines and consider non‑CYP3A4‑metabolized anxiolytics to prevent the interaction. 24

Regulatory and Safety Concerns

St. John’s wort products are not FDA‑regulated, resulting in variable content and potency across preparations, which limits reliable dosing and safety assessment. 24
Because of the lack of standardization, the herb’s interaction potential is unpredictable, reinforcing the need to obtain a complete herbal supplement history from any patient receiving alprazolam. 24

Contraindication of St. John’s Wort with Anticoagulants and Cardiovascular Medications

Major Drug Interactions

St. John’s Wort is a potent inducer of CYP3A4 and P‑glycoprotein, causing a marked reduction in apixaban plasma concentrations and increasing the risk of thromboembolic events such as stroke. 25
Co‑administration of St. John’s Wort with apixaban, atorvastatin, diltiazem, or sildenafil is considered absolutely contraindicated because the herb markedly lowers the plasma levels of these drugs, compromising their therapeutic efficacy. 26

Guideline Recommendations

The European Heart Rhythm Association explicitly advises that St. John’s Wort should not be used together with non‑vitamin K antagonist oral anticoagulants (NOACs), including apixaban, due to the clinically relevant decrease in anticoagulant levels. 26

Monitoring Recommendations When Interaction Occurs

If St. John’s Wort has been taken concurrently with apixaban, clinicians should promptly measure apixaban levels (where available), monitor the patient for signs of thromboembolism, and consider temporary bridging anticoagulation. 25